Los mejores oncólogos de Xofigo Radio-223 — TOP-26 médicos

Mustafa Solak, MD es un médico que se graduó de la Facultad de Medicina de la Universidad de Hacettepe y completó residencias en el Hospital de Investigación y Enseñanza Sisli Etfal de Estambul y una beca en el Instituto del Cáncer de la Universidad de Hacettepe. Se especializa en cáncer de mama, cáncer de testículo, cáncer de ovario, cáncer de pulmón, cáncer de cabeza y cuello y cánceres gastrointestinales. También ha trabajado en el Centro de Cáncer MD Anderson de la Universidad de Texas, el Hospital de Capacitación Corum de la Universidad Hitit y el Hospital Medical Park.

El principal especialista de Israel en el tratamiento del sarcoma y el cáncer de pulmón, Jefe del Centro Nacional de sarcomas de huesos y tejidos blandos del Centro Médico de Tel Aviv Sourasky (Ichilov)

Especialidad:

• Tratamiento de todo tipo de cáncer de pulmón y órganos torácicos
• Tratamiento de todo tipo de sarcomas de hueso y partes blandas
• Tratamiento tumores estromales del tracto gastrointestinal

Educación y especialización:

• Educación médica superior, graduado de la Facultad de Medicina de la Universidad Hebrea de Jerusalén, Israel
• Residencia en Oncología General y Radioterapia
• Formación en el campo de la radioterapia y braquiterapia en New York Hospital, USA
• Curso especial de actualización para el tratamiento de tumores del esqueleto y tejidos blandos, París. Francia

Afiliación:

• Presidente de la Sociedad de oncólogos y radioterapeutas de Israel
• La Sociedad Científica Americana del Cáncer
• organización médica científica europea
• Sociedad Europea de Oncología del sistema musculoesquelético
• Sociedad Internacional para el tratamiento de tumores del tejido conectivo

El Prof. Dr. Fatih Kurtuluş es Urólogo y FEBU (Fellow of European Board of Urology) que se graduó de la Universidad de Estambul, Facultad de Medicina de Cerrahpasa (inglés), en 1997. Tiene experiencia en los campos de endourología y urooncología y ha sido profesor de Urología desde 2018. Ha estado involucrado en diversas organizaciones y proyectos de investigación y ha publicado varios artículos en revistas arbitradas internacionales. También es miembro de varias asociaciones, como la Asociación Europea de Urología, la Sociedad Endourológica, la Asociación Turca de Urología y la Asociación de Urooncología.

El Prof. Dr. M. İhsan KARAMAN es cirujano urólogo y profesor de Urología con especialización en Crecimiento de próstata, cáncer de próstata, incontinencia urinaria, disfunción sexual, enfermedad de cálculos renales, infertilidad masculina y urología pediátrica. Ha ocupado varios cargos, incluido el de Jefe de la Clínica de Urología en el Hospital de Investigación y Capacitación Haydarpaşa Numune y Presidente de la Universidad Medeniyet de Estambul, y ha formado parte de varios comités nacionales e internacionales. También es miembro de varias organizaciones mundiales de la sociedad civil. Habla inglés y entiende árabe.

El Dr. Raj es un oncólogo quirúrgico altamente experimentado con 19 años de experiencia y más de 50,000 cirugías de cáncer realizadas. Está involucrado en numerosos ensayos clínicos y tiene muchas publicaciones internacionales y nacionales en su haber. Se especializa en Oncología Quirúrgica Torácica y de Mama y se desempeña como profesor de Oncología Quirúrgica de Superespecialidad DNB y Cirugía de Mama en la Universidad de Ciencias de la Salud de Maharashtra. Su creencia es "agregar vida a los años" y mejorar la calidad de vida, no solo agregar años a la vida.

Field of Speciality: Urology
Date of Birth: 1980
School of Medicine:  Istanbul University School of Medicine
Graduate Medical Education: University of Health Sciences Taksim Training & Research Hospital
Fellowship: Urological Oncology and Laparoscopic Urology Department of Urology SLK Kliniken Heilbronn University of Heidelberg, Germany
Foreign Language: English

Having graduated from Istanbul University, Faculty of Medicine in Istanbul, he pursued Urological Surgery residency at University of Health Sciences Taksim Training & Research Hospital, Istanbul from 2005 to 2010. He subsequently completed fellowship training in Urological Oncology and Laparoscopic Urology at Department of Urology, Heilbronn, Heidelberg University, Germany.Dr. Taş is able to provide patients curative surgery that is extremely precise, preserves sexual function, has minimal blood loss, minimal pain and quick recovery.

Firsts of Safe Urology Clinic in Turkey: Penis injections of:
Cellular derived from adipose tissue
Autologous bone marrow mesenchymal Cellular
Male-Shot

​

After graduating from Istanbul Medical Faculty in 2004, Dr. Tuncay Taş completed his specialization in Urology at Taksim Training and Research Hospital in 2010. After the training he received in 2006 and 2007 at the “Laparoscopy, Robotics and Oncology Center” of Heildelberg University, Heilbronn SLK Hospital, Germany, he continues to serve his patients in Turkey, especially in the field of Laparoscopic/Robotic Surgery. The majority of Tuncay Taş’s urology practice consists of man sexual health, cancer diagnosis and treatments

His sexual health and wellness practice offers cutting-edge technologies and treatment options for men. Dr Tas offers unique training and clinical protocols for practitioners who want to implement   Penile Implants , Penile Enhancement , SafeFill and MaleShot  into their practice. Dr Taş and his team presented the results of combined P.R.P (MALE-P-SHOT) and SVF application to the penis for the first time in Turkey at the scientific congress and shared the clinical results of these applications. It is also one of the first 5 centers in the world to publish the results of P.R.P (P.SHOT) applications. Dr Taş is one of the urology instructors at ISSCA who is fully involved in regenerative medicine.

(Source: At the congress organized by İHA International Cellular Therapies Association, Dr. Tuncay Taş shared his cell research in clinical regenerative medicine and erectile dysfunction. 2019, Sexual Medicine-Original Research2021, Apr;9(2):100313.doi:10.1016/j.esxm.2020.100313. Epub 2021 30 January.)

​

Recently Dr. Tas has developed a safe and effective treatment to improve penile circumference and has conducted training with a UK-based certification programme. This novel technique has been shown to have impressive and durable cosmetic results.

​

​

OTHER AREAS OF FOCUS

Robotic prostatectomy, Radical prostatectomy, HoLEP, Donor nephrectomy, Nephrectomy, Robotic surgery, Laparoscopic surgery, Prostate cancer, Kidney cancer, Bladder cancer, Testicular cancer, Retroperitoneal lymph node dissection for testicular cancer, Erectile dysfunction, Sexual dysfunction, Male infertility, Varicocelectomy, Male hypogonadism, Penile implant insertion, Urethroplasty, Penile reconstruction, Penile enlargement, Urethral reconstruction, Artificial urinary sphincter implantation, Bladder botox injection, Urodynamic testing, Bladder augmentation, Urinary diversion, Urethral stricture, Ureteral obstruction, HIPEC, Reconstructive surgery, Laparoscopic surgery, Fertility preservation, Minimally invasive surgery, Hypospadias

​

Membership of Scientific Organizations

Turkish Association of Urology
Turkish Medical Association
Association of Endourology
European Association of Urology
International Society for Stem Cells Applications

• Publications
https://scholar.google.com/citations?user=CA59D8UAAAAJ&hl=en

​

Experience

2021 - 2022

Clinical Manager of Radiation Oncology, Medicana International Istanbul Hospital

2021 - 2022

Department of Radiation Oncology, Biruni University Faculty of Medicine

2020 - 2021

Clinical Manager of Radiation Oncology, Medicana International Istanbul Hospital

2017 - 2020

Clinical Manager of Radiation Oncology, Neolife Medical Center

2016 - 2017

Department of Radiation Oncology, Eskişehir Osmangazi University Faculty of Medicine

2011 - 2016

Department of Radiation Oncology, Eskişehir Osmangazi University Faculty of Medicine

2010 - 2011

Department of Radiation Oncology, Eskişehir Osmangazi University Faculty of Medicine

2008 - 2010

Radiation Oncology Clinic, Samsun Training and Research Hospital (Education Coordinator)

2006

Medical Faculty, Dokuz Eylül University

2006 - 2008

Radiation Oncology Clinic, Samsun Mehmet Aydın State Hospital (Compulsory Service)

2000 - 2006

Medical Faculty, Dokuz Eylül University

Education

2022

Biruni University Faculty of Medicine, Department of Radiation Oncology, Faculty Member, Professor Doctor

2022

Anadolu University Open Education Faculty Undergraduate Program, Cultural Heritage and Tourism

2021

Feyziye Schools Foundation Işık University Health Services Vocational School, Faculty Member, Associate Professor Doctor

2017

Eskişehir Osmangazi University Faculty of Medicine, Department of Radiation Oncology, Faculty Member

2017

Eskişehir Osmangazi University Faculty of Medicine, Department of Radiation Oncology, Associate Professor Doctor

2006

Samsun Training and Research Hospital, Specialist Doctor, Compulsory Service

2006

Dokuz Eylül University Faculty of Medicine, Department of Radiation Oncology, Medical Specialization

1998

Ege University, Faculty of Medicine

PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

• Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
• Role: Subinvestigator

2. PFİZER

• Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
• Role: Subinvestigator

3. RECITE - AMGEN

• Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
• Role: Subinvestigator

4. NAVIGATE - BAYER

• Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• Role: Subinvestigator

5. RUBY - Tesaro (PRA)

• Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
• Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

• Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
• Role: Subinvestigator

7. ASTRA ZENECA

• Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
• Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

• Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
• Role: Subinvestigator
•  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
• Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
• Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

• Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
• Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

• Authors: Paksoy, Nail, et al.
• Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

• Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
• Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

• Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
• Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

• Authors: HAS SIMSEK, Duygu, et al.
• Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

• Authors: FERHATOGLU, Ferhat, et al.
• Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

• Authors: GÜRBÜZ, Mustafa, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

• Authors: AY, Seval, et al.
• Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

• Authors: CIL, Ibrahim, et al.
• Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

• Authors: HIZAL, Mutlu, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
• Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
• Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

• Authors: DEMIR, Semra, et al.
• Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

• Authors: ÖZDEMIR, Seçil Kepil, et al.
• Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

• Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
• Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

• Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
• Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
• Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
• Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

• Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
• Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

• Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
• Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

• Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
• Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

• Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
• Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

• Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
• Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

• Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

• Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

• Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

• Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

• Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

• Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

• Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

• Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

Experience

2017 - 2022 Haseki Training and Research Hospital, Associate Professor

2017 - 2022 Haseki Training and Research Hospital

2013 - 2017 Haseki Training and Research Hospital

2013 - 2017 Haseki Training and Research Hospital, Chief Resident

2010 - 2013 Silivri State Hospital (Compulsory Service Obligation)

2008 - 2008 University of Michigan Medical School

2005 - 2010 Istanbul Medical Faculty, Department of Urology

Education

2010 Istanbul University, Istanbul Medical Faculty, Department of Urology

2004 Istanbul University, Istanbul Medical Faculty

Publications

International Peer-Reviewed Journals:

Culpan M, Atis G, Sanli O, Bozkurt Y, Atmaca AF, Semerci B, Kutsal C, Canda AE, Akbulut F, Tugcu V, Boylu U, Erturhan S, Koca O, Ateş F, Halis F, Soyupek S, Turna B, Cakmak S, Sahin S, Erdem S, Yildirim A. "Comparison of Tumor Enucleation and Standard Partial Nephrectomy According to Trifecta Outcomes: A Multicenter Study by the Turkish Academy of Urology, Uro-Oncology Working Group." J Invest Surg. 2022 May;35(5):1112-1118.

Sahan M, Sarilar O, Akbulut MF, Demir E, Savun M, Sen O, Ozgor F. "Flexible ureterorenoscopy and laser lithotripsy with regional anesthesia vs general anesthesia: A prospective randomized study." Int Braz J Urol. 2020 Nov-Dec;46(6):1010-1018.

Cubuk A, Yanaral F, Savun M, Ayranci A, Erbin A, Yazici O, Akbulut MF, Sarilar O. "Modified autologous transobturator tape surgery - evaluation of short-term results." Ginekol Pol. 2020;91(2):51-56.

Kandemir E, Savun M, Sezer A, Erbin A, Akbulut MF, Sarilar Ö. "Comparison of Miniaturized Percutaneous Nephrolithotomy and Standard Percutaneous Nephrolithotomy in Secondary Patients: A Randomized Prospective Study." J Endourol. 2020 Jan;34(1):26-32.

Ucpinar B, Erbin A, Ayranci A, Caglar U, Alis D, Basal S, Sarilar O, Akbulut MF. "Prediction of recurrence in non-muscle invasive bladder cancer patients. Do patient characteristics matter?" J BUON. 2019 Jul-Aug;24(4):1659-1665.

Ozdemir H, Erbin A, Sahan M, Savun M, Cubuk A, Yazici O, Akbulut MF, Sarilar O. "Comparison of supine and prone miniaturized percutaneous nephrolithotomy in the treatment of lower pole, middle pole and renal pelvic stones: A matched pair analysis." Int Braz J Urol. 2019 Sep-Oct;45(5):956-964.

Erbin A, Ucpinar B, Cubuk A, Yazici O, Uysal H, Savun M, Basal S, Akbulut MF. "The Impact of Sheath Size in Miniaturized Percutaneous Nephrolithotomy in Adult Patients; A Matched-pair Analysis." Urol J. 2019 Dec 24;16(6):536-540.

Güler A, Erbin A, Ucpinar B, Savun M, Sarilar O, Akbulut MF. "Comparison of miniaturized percutaneous nephrolithotomy and standard percutaneous nephrolithotomy for the treatment of large kidney stones: a randomized prospective study." Urolithiasis. 2019 Jun;47(3):289-295.

Yanaral F, Ozgor F, Savun M, Agbas A, Akbulut F, Sarilar O. "Shock-wave Lithotripsy for Pediatric Patients: Which Nomogram Can Better Predict Postoperative Outcomes?" Urology. 2018 Jul;117:126-130.

Arslan B, Akbulut MF, Onuk O, Küçüktopçu O, Çilesiz NC, Ozkan A, Yazıcı G. "A comparison of Amplatz dilators and metal dilators for tract dilatation in mini-percutaneous nephrolithotomy." Int Urol Nephrol. 2017 Apr;49(4):581-585.

Akbulut F, Kucuktopcu O, Kandemir E, Ucpinar B, Ozgor F, Simsek A, Arslan B, Erbin A, Yanaral F, Binbay M, Gurbuz G. "Efficacy and safety of mini percutaneous nephrolithotomy in obese patients." Springerplus. 2016 Jul 22;5(1):1148.

Sancak EB, Oguz S, Akbulut T, Uludag A, Akbas A, Kurt O, Akbulut MF. "Female sexual dysfunction in androgenetic alopecia: Case-control study." Can Urol Assoc J. 2016, July;10(7-8):E251-256.

Akbulut F, Kucuktopcu O, Kandemir E, Sonmezay E, Simsek A, Ozgor F, Binbay M, Muslumanoglu AY, Gurbuz G. "Comparison of flexible ureterorenoscopy and mini-percutaneous nephrolithotomy in treatment of lower calyceal stones smaller than 2 cm." Ren Fail. 2016;38(1):163-7.

Tok A, Akbulut F, Buldu I, Karatag T, Kucuktopcu O, Gurbuz G, Istanbulluoglu O, Armagan A, Tepeler A, Tasci AI. "Comparison of microperc and mini-percutaneous nephrolithotomy for medium-sized lower calyx stones." Urolithiasis. 2016 Apr;44(2):155-9.

Akbulut F, Tok A, Penbegul N, Daggulli M, Eryildirim B, Adanur S, Gurbuz G, Celik H, Utangac MM, Dede O, Bodakcı MN, Tepeler A, Sarica K. "Colon perforation related to percutaneous nephrolithotomy: from diagnosis to treatment." Urolithiasis. 2015 Nov;43(6):521-6.

Ozluk Y, Sari S, Guzel NT, Firat P, Akbulut F, Kilicaslan I. "Mixed epithelial and stromal tumor of the kidney with sarcomatous transformation metastatic to the lung: A case report." Anal Quant Cytopathol Histpathol. 2015 Jun;37(3):199-205.

Ozgor F, Kucuktopcu O, Sarilar O, Toptas M, Simsek A, Gurbuz ZG, Akbulut MF, Binbay M. "Does previous open renal surgery or percutaneous nephrolithotomy affect the outcomes and complications of percutaneous nephrolithotomy." Urolithiasis. 2015 Nov;43(6):541-7.

Ugurlu İM, Akman T, Binbay M, Tekinarslan E, Yazıcı Ö, Akbulut MF, Özgör F, Müslümanoğlu AY. "Outcomes of retrograde flexible ureteroscopy and laser lithotripsy for stone disease in patients with anomalous kidneys." Urolithiasis. 2015 Feb;43(1):77-82.

Simsek A, Ozgor F, Kirecci SL, Akbulut MF, Sonmezay E, Yuksel B, Kucuktopcu O, Gurbuz ZG. "Results of tension-free vaginal tape for recurrent stress urinary incontinence after unsuccessful transobturator tape surgery." J Obstet Gynaecol Res. 2014 Jun;40(6):1764-9.

Simsek A, Kirecci SL, Kucuktopcu O, Ozgor F, Akbulut MF, Sarilar O, Ozkuvanci U, Gurbuz ZG. "Comparison of paroxetine and dapoxetine, a novel selective serotonin reuptake inhibitor in the treatment of premature ejaculation." Asian J Androl. 2014 Sep-Oct;16(5):725-7.

Akbulut F, Kucuktopcu O, Sonmezay E, Simsek A, Ozgor F, Gurbuz ZG. "Partial penectomy after debridement of a Fournier's gangrene progressing with an isolated penile necrosis." Ulus Travma Acil Cerrahi Derg. 2014 Sep;20(5):385-8.

Simsek A, Ozgor F, Yuksel B, Kucuktopcu O, Kirecci SL, Toptas M, Sarilar O, Berberoglu AY, Gurbuz ZG, Mimaroglu S, Akbulut F, Baykal M, Arslan B, Savun M, Ucpinar B. "Female sexual function after transobturator tape in women with urodynamic stress urinary incontinence." Springerplus. 2014 Sep 30;3:570.

Akbulut F, Akman T, Salabas E, Dincer M, Ortac M, Kadioglu A. "Neurovascular bundle dissection for Nesbit procedure in congenital penile curvature patients: medial or lateral?" Asian J Androl. 2014 May-Jun;16(3):442-5.

Kadioglu A, Sanli O, Akman T, Canguven O, Aydin M, Akbulut F, Kucukdurmaz F. "Factors Affecting the Degree of Penile Deformity in Peyronie's Disease: An Analysis of 1001 Patients." J Androl. 2011 Sep-Oct;32(5):502-8.

Akman T, Sanli O, Uluocak N, Akbulut F, Nane I, Demir S, Kadioglu A. "The most commonly altered type of Peyronie's disease deformity under oral colchicine treatment is lateral curvature that mostly shifts to the dorsal side." Andrologia. 2011 Feb;43(1):28-33.

Akbulut MF, Sanli O, Kadioglu A. "Editorial Comment on: Are Infertile Men Less Healthy than Fertile Men? Results of a Prospective Case-Control Survey." Eur Urol. 2009 Dec;56(6):1032.

Acar O, Akinci M, Uluocak N, Akbulut F, Kilicaslan I, Gokce O. "Paratesticular metastasis of malignant melanoma: a case report." Kaohsiung J Med Sci. 2008 Jun;24(6):315-8.

Çubuk A, Erbin A, Savun M, Ayranci A, Üçpınar B, Yanaral F, Sarılar Ö, Basal Ş, Akbulut MF. "Autologous transobturator midurethral sling." Turk J Urol. 2018 Dec 21;45(3):230-232.

Sarılar Ö, Özgör F, Küçüktopçu O, Uçpınar B, Akbulut MF, Savun M, Gürbüz ZG, Binbay M. "Is standard percutaneous nephrolithotomy still the standard treatment modality for renal stones less than three centimeters?" Turk J Urol. 2017 Jun;43(2):165-170.

Akbulut F, Savun M, Ucpinar B, Sahan M, Arslan B, Ozgor F, Simsek A, Berberoglu AY, Baykal M, Binbay M. "Duplicated Renal System with H Shaped Ureter: An Extraordinary Anomaly." Case Rep Urol. 2016;2016:4062515.

Akbulut F, Kucuktopcu O, Kandemir E, Sonmezay E, Simsek A, Ucpinar B, Ozgor F, Gurbuz G. "Comparison of efficacy of laser lithotripter with ultrasonic lithotripter in mini percutaneous nephrolithotomy." Arch Ital Urol Androl. 2016 Jan 14;87(4):276-9.

Ozgor F, Simsek A, Aydogdu O, Kucuktopcu O, Sarilar O, Berberoglu AY, Akbulut MF, Binbay M. "Bleeding during laparoscopic partial nephrectomy: Can a hemostatic matrix help to improve hemostasis?"

Dr. graduated from Istanbul Faculty of Medicine in 2004. Tuncay TAŞ, after the training he received at Heildelberg University, Germany, Heilbronn SLK Hospital "Laparoscopy, Robotics and Oncology Center" in 2006 and 2007, has served his patients for many years, especially in the field of Robotic and Laparoscopic surgery in Turkey. Dr. TAŞ completed his urology specialization in Istanbul in 2010.

The majority of urology practice consists of cancer diagnosis, treatment and follow-up; prostate, kidney, bladder diseases; microscopic varicocele operation, MicroTESE, sperm enhancing treatments, azoospermia, erectile dysfunction treatments and other testicular diseases in the field of men's health; HOLEP, Rezum and TUR Prostate surgery in the field of adult male health; urinary incontinence treatments in the field of women's health; minimally invasive kidney stone treatments in general urology; Surgical treatment of hypospadias and other urological disorders in children.

He works as a faculty member at the Private Urology Clinic (Safe Urology) and the University.

Scientific Organizations of which he is a Member

Turkish Urology Association

Turkish Medical Association

Endourology Association

European Association of Urology

International Stem Cell Applications Association

Specializations

Urological Oncology

Laparoscopic Urology

kidney problems

Neurourology

Penis Surgery

Education

2004

Istanbul Faculty of Medicine

medical School

2006 2007

University of Heidelberg, Germany

Scholarship: Urological Oncology and Laparoscopic Urology Department of Urology SLK Kliniken Heilbronn University of Heidelberg, Germany

2010

Health Sciences University Taksim Training and Research Hospital

Postgraduate Medical Education – Specialization in Urology